Felodipine in patients with organic solvent-induced chronic toxic encephalopathy. A double-blind, crossover study

Clinical Drug Investigation

Volumn 19, Issue 4, 2000, Pages 267-276

  Lindgren, May ^a,d   Thostrup, Hans ^b   Svannäs, Monica ^b   Fagher, Birger ^c  

^a LUND UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Department of Psychiatry ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BENZODIAZEPINE; DEXTROPROPOXYPHENE; DIURETIC AGENT; FELODIPINE; NEUROLEPTIC AGENT; PLACEBO; SOLVENT; THINNER;

ADULT; ARTICLE; BRADYCARDIA; BRAIN BLOOD FLOW; BRAIN TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; INSOMNIA; INTERVIEW; MALE; MEMORY; OCCUPATIONAL EXPOSURE; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SUSTAINED DRUG RELEASE; VERTIGO; WELLBEING;

EID: 0034048946     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019040-00004     Document Type: Article

References (39)

1. 1. Edling C, Ekberg K, Ahlborg Jr G, et al. Long term follow up of exposed workers to solvents. Br J Ind Med 1990; 47: 75-82
2. 2. Ørbæk P. Solvent-induced disability and recovery after cessation of exposure. In: Chang LW, Dyer RS, editors. Handbook of neurotoxicology. New York: Marcel Dekker, Inc., 1995: 339-53
3. 3. Lindgren M, Hagstadius S, Åbjörnsson G, et al. Neuropsychological rehabilitation of patients with organic solvent induced chronic toxic encephalopathy. Neuropsych Rehab 1997; 7 (1): 1-22
4. 4. Seppälainen AM, Lindström K, Martelin T. Neurophysiological and psychological picture of solvent poisoning. Am J Ind Med 1980; 1: 31-42
5. 5. Hänninen H. Twenty-five years of behavioral toxicology within occupational medicine: a personal account. Am J Ind Med 1985; 7: 19-30
6. 6. Ørbæk P, Lindgren M, Olivecrona H, et al. Computed brain tomography and psychometric test performances in patients with solvent induced chronic toxic encephalopathy and healthy controls. Br J Ind Med 1987; 44: 175-9
7. 7. Hagstadius S, Ørbæk P, Risberg J, et al. Regional cerebral blood flow at the time of diagnosis of chronic toxic encephalopathy induced by organic solvent exposure and after the cessation of exposure. Scand J Work Environ Health 1989; 15: 130-5
8. 8. Ørbæk P, Risberg J, Rosén I, et al. Effects of long-term exposure to solvents in the paint industry. A cross-sectional epidemiologic study with clinical and laboratory methods. Scand J Work Environ Health 1985; 11 Suppl. 2: 1-28
9. 9. Stein DG, Glasier MM, Hoffman SW. Pharmacological treatment for brain-injury repair: progress and prognosis. Neuropsych Rehab 1994; 4 (4): 337-57
10. 10. Tollefson GD. Short term effect of the calcium channel blocker nimodipine in the management of primary dementia. Biol Psychiatry 1990; 15; 27 (10): 1133-42
11. 11. Auer RN. Calcium channel antagonists in cerebral ischemia: a review. Drugs Develop 1993; 2: 307-17
12. 12. Finger S. Nimodipine and recovery from focal brain lesions. Drugs Develop 1993; 2: 379-93
13. 13. Thulin T, Fagher B, Grabowski M, et al. Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine. J Hypertens 1993; 11: 83-8
14. 14. Wiklund I, Halling K, Rydèn-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997; 6: 357-64
15. 15. Lindgren M, Thostrup H, Fagher B, et al. Calcium antagonist treatment in three cases of organic solvent induced chronic toxic encephalopathy [abstract no. 81], 2nd Pacific Rim Conference of the International Neuropsychological Society, and the Australian Society for Study of Brain Impairment; 1995 July 5-8: Cairns, Australia
16. 16. Ljung B. Vascular selectivity of felodipine: experimental pharmacology. J Cardiovasc Pharmacol 1990; 15 Suppl. 4: 11-6
17. 17. Jespersen BA, Jespersen LT, Pedersen OL. Greater blood pressure reduction with felodipine ER than with nitrendipine in hypertensive patients. A 24-hour ABPM study. Clin Drug Invest 1995; 10 (2): 65-70
18. 18. Ørbæk P, Lindgren M. Prospective clinical and psychometric investigation of patients with solvent induced chronic toxic encephalopathy. Scand J Work Environ Health 1988; 14: 37-44
19. 99MTc-HMPAO-SPECT in elderly women with senile dementia of Alzheimer's type. Dementia 1994; 5: 302-9
20. 20. Marsden CD, Harrison MJG. Outcome of investigation of patients with presenile dementia. BMJ 1972; 2: 249-52
21. 21. Bruhn P, Arlien-Søborg P, Gyldensted C, et al. Prognosis in chronic toxic encephalopathy. A two year follow-up study in 26 house painters with occupational encephalopathy. Acta Neurol Scand 1981; 64: 259-72
22. 22. Juntunen J, Antti-Poika M, Tola S, et al. Clinical prognosis of patients with diagnosed chronic solvent intoxication. Acta Neurol Scand 1982; 65: 488-503
23. 23. Morrow LA, Ryan CM, Hodgson MJ, et al. Alterations in cognitive and psychological functioning after organic solvent exposure. J Occup Med 1990; 32: 444-50
24. 24. Warkentin S, Passant U, Minthon L, et. al. Redistribution of blood flow in the cerebral cortex of normal subjects during head-up postural change. Clin Auton Res 1992; 2: 119-24
25. 25. Passant U, Warkentin S, Minthon L, et al. Cortical blood flow during head-up postural change in subjects with orthostatic hypotension. Clin Auton Res 1993; 3: 311-8
26. 26. Dureman I, Kebbon L, Österberg E. Manual till DS-batteriet. Stockholm: Psykologiförlaget, 1971
27. 27. Benton AL. The revised visual retention test. New York (NY): The Psychological Corporation 1974
28. 28. Graham FK, Kendall BS. Memory for designs. Revised general manual. Percept Mot Skills 1960; 11: 147-88
29. 29. Battle CC, Imber SD, Hoehn-Saric R, et al. Target complaints as criteria of improvement. Am J Psychother 1966; 20: 184-92
30. 30. Hansson L, Berglund M, Öhman R. Individualized measures of outcome versus standardized rating scales in the evaluation of psychiatric in-hospital treatment. Acta Psychiatr Scand 1987; 75: 275-82
31. 31. Dimenäs E, Dahlöf C, Olofsson B, et al. An instrument for quantifying subjective symptoms among untreated and treated hypertensives: development and documentation. J Clin Res Pharmacoepidemiol 1990; 4: 205-17
32. 32. Dimenäs E, Wallander M-A, Svärdsudd K, et al. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol 1991; 40: 141-7
33. 33. Wassertheil-Smollers S, Oberman A, Blanfox MD, et al. The trial of antihypertensive interventions and management (TAIM) study. Final results with regard to blood pressure, cardiovascular risks and quality of life. Am J Hypertens 1992; 5: 37-44
34. 34. Hjemdal P, Wiklund I. Quality of life on antihypertensive drug therapy: science end-point or marketing exercise? J Hypertens 1992; 10: 1437-46
35. 35. Dupuy HJ. The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CF, editors. Assessment of quality of life in clinical trials and cardiovascular therapies. New York: Le Jacq Publishing, Inc, 1984: 170-83
36. 36. Nilsson L-L, Levander S. Quality of life and schizophrenia. No subjective differences among four living conditions. Nord J Psychiatry 1998; 52: 277-83
37. 37. Hansson L, Svensson B, Björkman T. Quality of life of the mentally ill. Reliability of the Swedish version of the Lancashire Quality of Life Profile. Eur Psychiatry 1998; 13: 231-4
38. 38. Raichle ME, Fiez JA, Videen TO, et al. Practice-related changes in human brain functional anatomy during non-motor learning. Cereb Cortex 1994; 4: 8-26
39. 39. Lindberg G, Bingefors K, Ranstam J, et al. Use of calcium channel blockers and risk for suicide: ecological findings confirmed in population based cohort study. BMJ 1998; 316: 741-5